Literature DB >> 2346457

Abnormal uterine bleeding and cancer of the genital tract.

D G Allen1, J F Correy, D E Marsden.   

Abstract

All patients in Tasmania admitted to hospital for investigation of abnormal uterine bleeding in 1987 and 1988 were studied. A total of 4,318 patients were investigated. Four of 539 (0.7%) patients with intermenstrual or postcoital bleeding and 31 of 538 (5.8%) patients with postmenopausal bleeding were found to have endometrial cancer. Of the 3,421 patients investigated for 'heavy' periods (menorrhagia) there was no case of endometrial cancer. The detection rate of endometrial cancer on dilatation and curettage before the menopause is extremely low. Patients presenting with menorrhagia should not be treated surgically in the first instance unless an obvious organic cause is present.

Entities:  

Mesh:

Year:  1990        PMID: 2346457     DOI: 10.1111/j.1479-828x.1990.tb03204.x

Source DB:  PubMed          Journal:  Aust N Z J Obstet Gynaecol        ISSN: 0004-8666            Impact factor:   2.100


  4 in total

1.  Endometrial pipelle biopsy compared to conventional dilatation and curettage.

Authors:  S Ong; T Duffy; P Lenehan; J Murphy
Journal:  Ir J Med Sci       Date:  1997 Jan-Mar       Impact factor: 1.568

Review 2.  A systematic review of postcoital bleeding and risk of cervical cancer.

Authors:  Mark Shapley; Joanne Jordan; Peter R Croft
Journal:  Br J Gen Pract       Date:  2006-06       Impact factor: 5.386

3.  Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women: A Systematic Review and Meta-analysis.

Authors:  Megan A Clarke; Beverly J Long; Arena Del Mar Morillo; Marc Arbyn; Jamie N Bakkum-Gamez; Nicolas Wentzensen
Journal:  JAMA Intern Med       Date:  2018-09-01       Impact factor: 21.873

Review 4.  Premenopausal abnormal uterine bleeding and risk of endometrial cancer.

Authors:  M E Pennant; R Mehta; P Moody; G Hackett; A Prentice; S J Sharp; R Lakshman
Journal:  BJOG       Date:  2016-10-20       Impact factor: 6.531

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.